JP2004524806A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004524806A5 JP2004524806A5 JP2002507992A JP2002507992A JP2004524806A5 JP 2004524806 A5 JP2004524806 A5 JP 2004524806A5 JP 2002507992 A JP2002507992 A JP 2002507992A JP 2002507992 A JP2002507992 A JP 2002507992A JP 2004524806 A5 JP2004524806 A5 JP 2004524806A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- chimeric protein
- seq
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 description 22
- 102000037865 fusion proteins Human genes 0.000 description 13
- 108020001507 fusion proteins Proteins 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 108010029697 CD40 Ligand Proteins 0.000 description 5
- 102100032937 CD40 ligand Human genes 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 5
- 239000002955 immunomodulating agent Substances 0.000 description 5
- 230000002584 immunomodulator Effects 0.000 description 5
- 229940121354 immunomodulator Drugs 0.000 description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 5
- 102000003814 Interleukin-10 Human genes 0.000 description 4
- 108090000174 Interleukin-10 Proteins 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 102000013462 Interleukin-12 Human genes 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 102000003812 Interleukin-15 Human genes 0.000 description 3
- 108090000172 Interleukin-15 Proteins 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 102100035304 Lymphotactin Human genes 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 108010019677 lymphotactin Proteins 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 101710112752 Cytotoxin Proteins 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- JJGWLCLUQNFDIS-GTSONSFRSA-M sodium;1-[6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCNC(=O)CCCC[C@H]1[C@H]2NC(=O)N[C@H]2CS1 JJGWLCLUQNFDIS-GTSONSFRSA-M 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21558000P | 2000-06-30 | 2000-06-30 | |
| PCT/US2001/020946 WO2002002751A2 (en) | 2000-06-30 | 2001-07-02 | Alteration of cell membrane |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004524806A JP2004524806A (ja) | 2004-08-19 |
| JP2004524806A5 true JP2004524806A5 (https=) | 2008-08-07 |
Family
ID=22803538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002507992A Pending JP2004524806A (ja) | 2000-06-30 | 2001-07-02 | 新しい機能のための細胞膜の変更 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US7238360B2 (https=) |
| EP (1) | EP1299522B1 (https=) |
| JP (1) | JP2004524806A (https=) |
| AT (1) | ATE531789T1 (https=) |
| AU (2) | AU1676302A (https=) |
| CA (1) | CA2413237C (https=) |
| WO (1) | WO2002002751A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7927602B2 (en) * | 2002-07-23 | 2011-04-19 | University Of Louisville Research Foundation, Inc. | Fas ligand-avidin/streptavidin fusion proteins |
| AU1676302A (en) | 2000-06-30 | 2002-01-14 | Univ Louisville Res Found | Alteration of cell membrane for new functions |
| WO2003106640A2 (en) | 2002-06-14 | 2003-12-24 | Case Western Reserve University | Cell targeting methods and compositions |
| US7373559B2 (en) * | 2003-09-11 | 2008-05-13 | Copan Systems, Inc. | Method and system for proactive drive replacement for high availability storage systems |
| NZ562946A (en) * | 2005-04-29 | 2011-08-26 | Univ Louisville Res Found | Cell-surface decoration with active agents |
| CA2611861C (en) | 2005-06-08 | 2017-11-28 | The Brigham And Women's Hospital, Inc. | Methods and compositions for the treatment of persistent infections |
| WO2007067683A2 (en) * | 2005-12-08 | 2007-06-14 | University Of Louisville Research Foundation, Inc. | Methods and compositions for expanding t regulatory cells |
| MX2008007292A (es) * | 2005-12-08 | 2008-10-17 | Univ Louisville Res Found | Composiciones inmunoestimuladoras y metodos. |
| US10407672B2 (en) * | 2006-03-27 | 2019-09-10 | Seattle Children's Hospital | Compositions and methods comprising the use of cell surface displayed homing endonucleases |
| KR101523391B1 (ko) * | 2006-12-27 | 2015-05-27 | 에모리 유니버시티 | 감염 및 종양 치료를 위한 조성물 및 방법 |
| MX2011005691A (es) * | 2008-11-28 | 2011-07-20 | Univ Emory | Metodos para el tratamiento de infecciones y tumores. |
| WO2012011113A2 (en) * | 2010-07-22 | 2012-01-26 | Shai Yarkoni | Regulatory immune cells with enhanced targeted cell death effect |
| EP3313429B1 (en) * | 2015-06-19 | 2021-10-06 | University Of Louisville Research Foundation, Inc. | Immunomodulation for the long term prevention and treatment of autoimmune diseases and foreign tissue rejection |
| JP6974681B2 (ja) | 2015-07-29 | 2021-12-01 | オーエヌケー セラピューティクス リミテッド | 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株 |
| US10906951B2 (en) | 2015-07-29 | 2021-02-02 | Onk Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| EP3592392B1 (en) * | 2017-03-10 | 2023-09-13 | University of Louisville Research Foundation, Inc. | Fasl-engineered biomaterials with immunomodulatory function |
| CA3096533C (en) * | 2018-04-27 | 2023-08-29 | Aimed Bio Inc. | Magnetic-based biopanning method through attachment of magnetic bead to cell |
| US11504335B2 (en) | 2018-06-18 | 2022-11-22 | University Of Kentucky Research Foundation | Increased cell retention in diseased site when cells encapsulated in gelatin methacrylate and polyethylene glycol diacrylate hydrogels |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991001004A1 (en) * | 1989-07-06 | 1991-01-24 | Seragen, Inc. | Hybrid molecules |
| US6071716A (en) | 1990-10-01 | 2000-06-06 | Dana-Farber Cancer Institute | DNA encoding, B7, a new member of the IG superfamily with unique expression on activated and neoplastic B cells |
| US5470701A (en) * | 1993-02-24 | 1995-11-28 | The Regents Of The University Of California | Method for determining favorable prognosis in an HIV positive subject using HLA-DR+ /CD38- CD8bright cells |
| US6130316A (en) | 1993-07-26 | 2000-10-10 | Dana Farber Cancer Institute | Fusion proteins of novel CTLA4/CD28 ligands and uses therefore |
| US5858776A (en) | 1993-11-03 | 1999-01-12 | Repligen Corporation | Tumor cells with increased immunogenicity and uses therefor |
| US6218510B1 (en) | 1994-03-02 | 2001-04-17 | Brigham & Woman's Hospital | B7-1 and B7-2 polypeptides |
| DK1666591T3 (da) | 1995-06-29 | 2011-05-23 | Immunex Corp | Cytokin der inducerer apoptose |
| JP2001520636A (ja) | 1995-08-30 | 2001-10-30 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | 慢性炎症性疾患における細胞蓄積の治療 |
| GB9523469D0 (en) | 1995-11-16 | 1996-01-17 | Sandoz Ltd | Organic compounds |
| WO1997033617A1 (en) | 1996-03-13 | 1997-09-18 | Protein Design Labs, Inc. | Fas ligand fusion proteins and their uses |
| US6060054A (en) * | 1996-04-10 | 2000-05-09 | National Jewish Medical And Research Center | Product for T lymphocyte immunosuppression |
| AU5437098A (en) | 1996-11-15 | 1998-06-03 | Health Research Inc. | A method for inducing apoptosis of primary central nervous system b cell lymphomas |
| GB9721075D0 (en) * | 1997-10-03 | 1997-12-03 | Cancer Res Campaign Tech | Materials and methods relating to the stimulation of cells |
| US7144991B2 (en) * | 1999-06-07 | 2006-12-05 | Aletheon Pharmaceuticals, Inc. | Streptavidin expressed gene fusions and methods of use thereof |
| JP2003517311A (ja) | 1999-12-16 | 2003-05-27 | ユニバーシティ オブ ルイビル リサーチ ファウンデーション，インコーポレイティド | カスパーゼにより誘導されるアポトーシスのための組成物および方法 |
| CA2396979C (en) * | 2000-01-24 | 2015-07-14 | University Of Louisville Research Foundation, Inc. | Immune modulation with death receptor-induced apoptosis |
| US7927602B2 (en) * | 2002-07-23 | 2011-04-19 | University Of Louisville Research Foundation, Inc. | Fas ligand-avidin/streptavidin fusion proteins |
| AU1676302A (en) | 2000-06-30 | 2002-01-14 | Univ Louisville Res Found | Alteration of cell membrane for new functions |
| WO2007067683A2 (en) * | 2005-12-08 | 2007-06-14 | University Of Louisville Research Foundation, Inc. | Methods and compositions for expanding t regulatory cells |
| MX2008007292A (es) * | 2005-12-08 | 2008-10-17 | Univ Louisville Res Found | Composiciones inmunoestimuladoras y metodos. |
-
2001
- 2001-07-02 AU AU1676302A patent/AU1676302A/xx active Pending
- 2001-07-02 AT AT01984107T patent/ATE531789T1/de active
- 2001-07-02 JP JP2002507992A patent/JP2004524806A/ja active Pending
- 2001-07-02 CA CA2413237A patent/CA2413237C/en not_active Expired - Fee Related
- 2001-07-02 WO PCT/US2001/020946 patent/WO2002002751A2/en not_active Ceased
- 2001-07-02 AU AU2002216763A patent/AU2002216763B2/en not_active Ceased
- 2001-07-02 EP EP01984107A patent/EP1299522B1/en not_active Expired - Lifetime
- 2001-07-02 US US10/312,245 patent/US7238360B2/en not_active Expired - Lifetime
-
2007
- 2007-06-25 US US11/819,080 patent/US8076096B2/en not_active Expired - Fee Related
-
2011
- 2011-12-12 US US13/316,915 patent/US8728747B2/en not_active Expired - Fee Related
-
2014
- 2014-05-19 US US14/280,940 patent/US9255133B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004524806A5 (https=) | ||
| JP4568907B2 (ja) | 免疫賦活オリゴヌクレオチド及びその使用 | |
| JP2001524320A5 (https=) | ||
| Weber et al. | Clinical management of Lyme borreliosis. | |
| JP2002542827A5 (https=) | ||
| JP2003529608A5 (https=) | ||
| HU230702B1 (hu) | Eljárás jopamidol előállítására | |
| JP2005512518A5 (https=) | ||
| Wulf et al. | An old sweet song. | |
| Gorman et al. | Battling the AIDS virus. | |
| Fricker | New asthma drug proves useful in young children. | |
| Lawrence | Nanotechnology takes another small step forward | |
| Gorman et al. | The odds grow longer. | |
| Majnarich | Method for preparing a purified extraction residue fraction and its use in stimulating the immune response | |
| Butcher | Wake-up call for sleep-inducing neurons. | |
| Gibbs et al. | LIFE ALONG THE MISSISSIPPI. | |
| Kumar | Last chance'to control tuberculosis in India. | |
| Farley et al. | Just in case you hadn't heard--the'60s are over. | |
| Handy | Have gigabytes, will act. | |
| Murr | Starting to accept'the worst' | |
| Huffman | Levomethadyl acetate for opioid-dependent patients. | |
| McIntyre et al. | Immunisation in the age of the human genome | |
| Barovick et al. | It's Beginning to Sound A Lot Like Christmas Past. | |
| Howard et al. | Shot Through The Heart. | |
| Featherstone | Chaperoning tumour antigens into the immune system. |